SCHEMBL3337136

SCHEMBL3337136

CN1CCC(c2c[nH]c3cc([N+](=O)[O-])ccc23)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.57
HTR1D P28221 8/20 0.53
HTR1B P28222 8/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
THPO P40225 1/20 0.53
HTR1F P30939 4/20 0.52
HTR1A P08908 4/20 0.52
KDM4E B2RXH2 1/20 0.49
ATM Q13315 1/20 0.49
MAPT P10636 1/20 0.48
BLM P54132 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SLC6A4 P31645 2/20 0.48
DRD2 P14416 1/20 0.48
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
NOS2 P35228 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640192 0.90 HTR1D (0.63) APPHTR1DHTR1BCYP1A2CYP3A4
SCHEMBL7881156 0.83 HTR2C (0.55) APP
SCHEMBL7845256 0.83 HTR1D (0.55) APPHTR1DHTR1BCYP1A2CYP3A4
Fumaric Acid SCHEMBL7867909 0.80 CCR2 (0.50) HTR1DHTR1BHTR1FHTR1AKDM4E
Fumaric Acid SCHEMBL7867913 0.80 CCR2 (0.50) HTR1DHTR1BHTR1FHTR1AKDM4E
Maleic Acid SCHEMBL7867904 0.80 CCR2 (0.50) HTR1DHTR1BHTR1FHTR1AKDM4E
SCHEMBL3337495 0.79 PKM (0.41) APPHTR1DHTR1BHTR1FHTR1A
SCHEMBL23010845 0.79 APP (0.64) APPHTR1DHTR1BCYP1A2CYP3A4
SCHEMBL21088266 0.78 HTR1D (0.80) APPHTR1DHTR1BCYP1A2CYP3A4
SCHEMBL21088140 0.78 APP (0.63) APPHTR1DHTR1BCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2022-02-15 US disclosed
US-20200377520-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2020-12-03 US disclosed
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-06-17 US disclosed
US-7696229-B2 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-13 US disclosed
EP-1984351-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY Memory Pharmaceuticals Corporation (US) 2008-10-29 EP disclosed
US-20080039462-A1 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION 2008-02-14 US disclosed
WO-2007098418-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377520-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF WEE1, WEE2, PDPK1 APP 4576/4885HTR1D 2818/4885HTR1B 4112/4885
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR3B, HTR1B APP 3410/4885HTR1D 11/4885HTR1B 3/4885
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof WEE1, WEE2, PDPK1 APP 4576/4885HTR1D 2818/4885HTR1B 4112/4885
US-20080039462-A1 Compounds having 5-HT6 receptor affinity HTR6, HTR3B, HTR1B APP 3410/4885HTR1D 11/4885HTR1B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.